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Glioblastoma is an aggressive tumour of the central nervous system, with limited survival and 
poor treatment options. The standard therapy consists of surgical resection followed by 
radiation therapy and chemotherapy with Temozolomide (TMZ). Patients with glioblastoma 
have a low life expectancy and even after treatment, recurrence is almost certain. Research 
its being made to find new therapies that can improve the standard treatment and prognosis. 
With the advances of science, the pioneering therapies comprise targeted therapies, 
immunotherapy, virotherapy, gene therapy, among others. Targeted therapies consider the 
many pathways that tumour uses to grow and survive, such as receptor tyrosine 
kinase/phosphoinositide 3-kinasen/mitogen-activated protein Kinase (RTK/PI3K/MAPK) 
pathway, p53 and retinoblastoma protein (pRb) pathways, and other important signalling 
transduction pathways, such as polyamine biosynthetic pathway. With the knowledge of which 
proteins and genes contribute to the proliferation of the tumour, that information can be used 
to target the cancer cells and restrain the glioblastoma growth. The immunotherapy uses the 
immune system of the patient as a pathway to fight the tumour and includes CAR-T cells 
therapy, TIL therapy, TCR therapy, vaccination and immune checkpoint inhibition. The 
virotherapy uses the oncolytic activity of the virus to target the tumour cells and destroy them. 
Gene therapy inserts, modifies or inactivates a gene in order to fight the disease. Additionally, 
there are other different therapies being investigated, that consider other mechanisms, such 
as the cholesterol metabolism and hyperthermia. 
Since glioblastoma is a fatal disease, more options for treatment are needed to improve quality 
of life and the overall survival of the patients. The purpose of this dissertation is to analyse the 
future of glioblastoma treatments, looking to the innovative therapeutic approaches that are 
under development Although these new therapies, look promising to assemble a new 
treatment, issues related to the tumour itself, to the central nervous system and to clinical trials 

















Ana Beatriz Bogalho, Orientador: Professora Doutora Cristina Carvalho 




ABSTRACT ............................................................................................................................................. 3 
INTRODUCTION ..................................................................................................................................... 5 
CLASSIFICATION OF GLIOBLASTOMAS ...................................................................................................... 5 
GLIOMAGENESIS .................................................................................................................................... 6 
ANGIOGENESIS ...................................................................................................................................... 7 
CLINICAL PRESENTATION ....................................................................................................................... 7 
DEVELOPMENT OF NOVEL THERAPIES FOR GBM – CHALLENGES ............................................................. 7 
GLIOBLASTOMA CURRENT TREATMENT OPTIONS ........................................................................ 8 
SURGERY .............................................................................................................................................. 8 
RADIOTHERAPY (RADIATION THERAPY) ................................................................................................... 8 
CHEMOTHERAPY .................................................................................................................................... 8 
TUMOUR TREATING FIELDS (TTFS) ....................................................................................................... 10 
NITROSOUREAS ................................................................................................................................... 10 
▪ Gliadel wafers ........................................................................................................................ 10 
▪ Lomustine (CCNU) ................................................................................................................ 11 
BEVACIZUMAB ...................................................................................................................................... 11 
INNOVATIVE THERAPEUTIC APPROACHES TO FIGHT GLIOBLASTOMA ................................... 12 
TARGETED THERAPIES ......................................................................................................................... 12 
▪ RTK/PI3K/MAPK Pathways ................................................................................................... 12 
• Epidermal Growth Factor Receptor inhibitors (EGFR) ..................................................................... 14 
• Platelet-Derived Growth Factor Receptor (PDGFR) ........................................................................ 15 
▪ p53 Pathway .......................................................................................................................... 16 
▪ Retinoblastoma protein (pRb) Pathway ................................................................................. 16 
▪ Others .................................................................................................................................... 17 
• Polyamine Biosynthetic Pathway ..................................................................................................... 17 
IMMUNOTHERAPY ................................................................................................................................. 17 
▪ Adoptive cellular therapies (ACT) .......................................................................................... 17 
• CAR-T Cells Therapy ....................................................................................................................... 17 
• TIL Therapy ..................................................................................................................................... 18 
• TCR Therapy ................................................................................................................................... 18 
▪ Vaccine Therapy .................................................................................................................... 18 
• Dendritic Cell Vaccines .................................................................................................................... 18 
• Peptide Vaccines ............................................................................................................................. 19 
• Heat Shock Protein Vaccination ...................................................................................................... 19 
▪ Checkpoint Inhibition ............................................................................................................. 20 
VIROTHERAPY ...................................................................................................................................... 20 
GENE THERAPY ................................................................................................................................... 21 
OTHER POTENTIAL THERAPIES ............................................................................................................. 21 
▪ Cholesterol Metabolism ......................................................................................................... 21 
▪ Hyperthermia ......................................................................................................................... 21 
CONCLUSION ...................................................................................................................................... 22 





Ana Beatriz Bogalho, Orientador: Professora Doutora Cristina Carvalho 




Glioblastoma is the most aggressive and common tumour of the central nervous system 
(CNS), having a fast-growing and invasiveness that leads to a high morbidity and mortality 
(1,2). 
Considering it is an heterogenous brain tumour, with fast-development, recurrence is usual 
and inevitable. The tumour exhibits significant resistance to the therapy and, treatment options 
for recurrent disease are rather limited (3,4). 
Classification of Glioblastomas 
The term ‘glioblastoma multiforme’ (GBM) was introduced in 1926 by Cushing and Bailey to 
describe the heterogeneity found on the histologic examination of glioblastoma cells. (2,5) This 
classification was replaced by the 2007 World Health Organization (WHO) Classification of 
Tumors of the Central Nervous System (2,6). 
Nowadays, and according to the 2016 World Health Organization Classification of Tumors of 
the Central Nervous System, glioblastomas are classified as IV grade diffuse astrocytic and 
oligodendroglial tumours (7,8). This classification divides CNS tumours following the genotypic 
and phenotypic features. Hence, glioblastomas can be divided in three vast groups, according 
to the existence or inexistence of mutations in isocitrate dehydrogenase (IDH): glioblastoma 
IDH-wildtype, glioblastoma IDH-mutant and Glioblastoma, Not wised specified (NOS), as 
showed in figure 1(7).  
 
Figure 1 – Algorithm, based in the 2016 World Health Organization Classification of Tumours of the Central 
Nervous System, to systematise the different types of Glioblastomas. 
Adapted from Louis DN, Perry A, Reifenberger Guido, Von Deimling A, Figarella-Branger D, Webster·, et al. The 2016 
World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, (7). 
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Glioblastoma IDH-wildtype is the most common type (approximately 90% of cases), affecting 
older patients (media of ages is 62 years). It is defined as primary glioblastoma or de novo 
glioblastoma due to its rapid progression from non-neoplastic brain cells without a precursor 
lesion. Usually, it is in the supratentorial region and is defined by the extensive necrosis and 
the existence of mutation in the Telomerase Reverse Transcriptase (TERT) promoter in 72% 
of cases. The median overall survival (OS) with the gold-standard of therapy is 15 months. In 
this group, we can also add gliosarcoma, epithelioid glioblastoma and giant cell glioblastoma, 
with a similar molecular profile but a different morphology (7–9). 
Glioblastoma IDH-mutant (about 10% of cases), corresponds to the secondary glioblastoma, 
developing from a prior lower grade diffuse glioma. It affects younger patients (media of ages 
is 44 years) and is located preferentially in the frontal region. It has a limited necrosis, having 
TP53 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutations in 81% 
and 71% of cases, respectively. The OS with the standard treatment is 31 months, having a 
better prognosis than Glioblastoma IDH-wildtype (7–9). 
Glioblastoma NOS corresponds to the glioblastomas in which the IDH classification is not 
possible, either because the test is not done or because is inconclusive (7,9). This means that 
the diagnosis is made based only on histologic features (9). 
The different mutations present in glioblastomas are considered diagnostic biomarkers and 
help differentiate the tumours, giving more information that can be used to identify the best 
treatment option (9). Nowadays, there are several new biomarkers, but the ones that are 
commonly used in a daily routine are: IDH (prognostic value, referred to previously), O-6-
methylguanine-DNA methyltransferase (MGMT), and 1p/19q co-deletion (predictive) (1). We 
can divide patients with glioblastoma concerning the presence or absence of the methylation 
in the promoter of O-6-methylguanine-DNA methyltransferase (MGMT) gene, which encodes 
a protein that repairs DNA damages. This promoter methylation is connected with a low activity 
on repairing DNA giving a better prognosis with the current chemotherapy treatment – 
Temozolomide (TMZ) (3,10). 
Gliomagenesis 
Although many studies have been done and new biomarkers, gene mutations have been 
found, the exact mechanism of gliomagenesis is uncertain. It is thought that the cellular origin 
is from primitive pluripotent cells, including neural stem cells, glial precursor cells, and 
oligodendrocyte precursor cells (2). There is also a consensus that GBM incorporates cancer 
stem cells (CSCs), cancer-initiating cells, and cancer-propagating cells that have the ability of 
self-renewal and tumor initiation that leads, briefly, to the development of a new tumour, 
resulting in resistance to the current therapy (11,12). It is assumed that the gliomagenesis is a 
phased process, involving different potential genetic changes (13). 
The Cancer Genome Atlas (TCGA) has identified some pathways that are disrupted and that 
have been linked to the development of glioblastoma: receptor tyrosine 
kinase/phosphoinositide 3-kinase/mitogen-activated protein kinase (RTK/PI3K/MAPK) (almost 
90% of the cases), p53 (86% of the tumours) and retinoblastoma protein (pRb) (79%) 
pathways. The RTKs when activated stimulates the PI3K pathway that controls cellular events. 
The p53 and RB genes are typical tumour suppressor genes that inactivate mutations in the 
cell cycle (G1 to S phase). This genetic and molecular identification allowed for an additional 
classification of glioblastoma,in 4 subtypes: classical GBM, mesenchymal GBM, proneural 
GBM and neural GBM. (14–16). 
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Although some of the mechanisms that lead to gliomagenesis are known, there is no specific 
cause for the development of glioblastoma, for most patients. Researchers have studied many 
possible risk factors such as environmental and behavioural but there is no minimal evidence 
of association to GBM, therefore it is impossible to decrease the incidence as done for other 
types of tumours (1,17). The only cause recognised as GBM risk factor is exposure to radiation. 
This is only for a minority of the patients with GBM, being other possible causes, the genetic 
predisposition to tumorigenesis (leading to different tumours including GBM) or also a strong 
family history of cancer (1,17,18). On other hand, there is a reduced glioblastoma risk for those 
who have allergies, autoimmune diseases, reported history of varicella-zoster virus (VZV) 
infections or the presence of Immunoglobulin G (IgG) to VZV (17). 
Angiogenesis 
Angiogenesis is a key process in the development and survival of tumours being the adequate 
blood supply a known feature. In the case of Glioblastoma it is extremely vascularized (19,20). 
The establishment of these complex blood vessels is coordinated by several angiogenic 
factors, such as, Vascular Endothelial Growth Factor (VEGF), basic Fibroblast Growth Factor 
(bFGF) and Platelet-Derived Growth Factor (PDGF) (19). 
Clinical Presentation 
The clinical presentation of glioblastoma is connected to the area of the brain that is affected, 
but also with the size and rate of growth of the GBM. Usually, the symptoms are presented 
when the tumour is in an advance state and they can be confused with other diseases. These 
symptoms are subtle and include headaches, fatigue, neurologic deficits. Seizures can also 
occur in some patients (1,18,19). 
Development of Novel Therapies for GBM – Challenges 
Developing new therapies for GBM is a challenge since CNS and GBM itself are complex 
structures. Many obstacles can be pointed out as the cause of failure of new therapies and 
many obstacles remain unknown (18). 
There can be some potential barriers in the developing stages of the potential treatments. The 
preclinical models are not representative of GBM and it is impossible to collect all the needed 
information from them (1,18). Therefore, there is the need of better models and there is the 
necessity to optimize the clinical protocols and to create clinical trials that estimate the 
effectiveness of the therapy instead of overestimating the probability of success that leads to 
late-stage failure (18,21,22). 
Other potential barriers are connected to the characteristics of the CNS and Glioblastoma. 
Glioblastoma is characterized as an heterogenous tumour, with many deregulated pathways 
that lead to therapy resistance. One challenge is the difficulty to cure GBM with a single 
therapy, since GBM has many targets, and many resistant mechanisms (1,11). Secondly, the 
GBM has abnormal vessels and areas of necrosis that prevent a good distribution of the 
medicine (18). Also, the brain impairs drug delivery by having a physic and metabolic barrier 
,the Blood Brain Barrier (BBB), that can prevent the entrance of the medicine or efficiently 
pump the medicine out, through the efflux pumps (18,21,23).The drug delivery is a challenge. 
When assessing a new therapy, it is required to look at the characteristics of the medicine: it 
should be permeable to the BBB (having the right lipophilicity and size) and they should reach 
a therapeutic concentration even if distribution is not homogeneous (21). 
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Glioblastoma Current Treatment Options 
 
The current standard of treatment involves maximal surgical resection followed by radiation 
therapy and concomitant Temozolomide (TMZ), with subsequent adjuvant chemotherapy with 
TMZ for 6 to 12 months, for patients with ages lower than 70 years (3,4,18,24,25). The 
maintenance therapy can also be combined with Tumor Treating Fields (TTF’s) (24,26).  
The prognosis of the treatment is dependent on the type of glioblastoma, as referred 
previously. 
The treatment options for recurrence are more restricted and involve the use of 
chemotherapeutic agents (mostly, nitrosoureas) and monoclonal antibodies such as 
bevacizumab (not approved in Europe), an inhibitor of vascular endothelial growth factor 
(VEGF), important in tumour angiogenesis (26). Since there is an absence of a specific 
guideline to advise the best therapy, treatment options are made based on numerous factors, 
namely: age, tumour extent and site, preceding therapies and the length of the disease. Even 
treating recurrent glioblastoma, the median overall survival is 6.2 months, being the longest 
OS achieved of 12 months, with bevacizumab plus lomustine (alkylating nitrosourea). (21) 
Surgery 
Surgery is the initial treatment. It is also a diagnostic tool, as it enables a molecular diagnosis 
(1,2). 
The retrospective data shows that the surgery has a better outcome if the resection is 
performed to the safe highest extent (1,18). Although, due to the infiltrative nature of this type 
of tumour, the complete resection is not a sign that the disease is cured, as the GBM cells can 
remain and form a new tumour (1,2). 
Considering the limitations of the current surgical methods, many new procedures are under 
development (1). Table 1 exposes some of the new elaborated practises of the surgical field. 
Radiotherapy (Radiation Therapy) 
Radiotherapy plays a key role in the treatment of glioblastoma as it is an effective treatment 
shown to improve survival. The standard dose is 60 Gy in 30 fractions, 3 or 4 weeks after the 
surgery, being the duration of the treatment 6 weeks (2,3,18). Patients with characteristics that 
point to a worst diagnosis such as more than 70 years old, are generally treated with hypo 
fractioned radiation (dose of 40 Gy administered in 15 fractions) (25). With these schemes of 
therapy, the cancer cells are killed considering that the radiation stops the cell cycle and 
induces apoptosis (3). 
Since radiotherapy is one important tool in glioblastoma therapy, there are different new 
techniques being established. Table 1 displays the different radiotherapy methods being 
explored. 
Chemotherapy 
Chemotherapy uses the alkylation agent TMZ, that breaks DNA double-strand and decreases 
the activity of MGMT (DNA repair enzyme), stimulating cell cycle arrest and cell death (1,27). 
This is the first-line therapy drug in combination with radiotherapy (3). In a Phase III clinical  
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Table 1 – Innovations and new techniques within glioblastoma therapy to improve the outcome, focusing 
in 3 fields: Surgery, Radiotherapy, Chemotherapy. Adapted from Alphandéry E. Glioblastoma Treatments: An 
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trial, using TMZ plus radiotherapy, followed by adjuvant TMZ for 6 months, the results have 
shown that the overall survival improved when comparing to radiotherapy alone. Even when a 
trial was conducted in an elderly population, the results were as positive, leading to a longer 
survival (28,29). TMZ is used at a daily dose of 150-200mg/m2 of body surface-area (BSA) for 
5 days every 28-day cycle (1). 
As mentioned before, there is the possibility of resistance to TMZ when there is a 
demethylation from O6 position of guanine by O6-methylguanine methyltransferase (MGMT) 
(27). Hence, the patients that have a methylated MGMT and supressed MGMT expression, 
benefit with chemotherapy with TMZ, having a better prognosis and an improved 2-year 
survival (1,27,30). 
Considering that one of the biggest challenges in glioblastoma therapy is drug delivery of 
chemotherapeutic agents, in table 1 there are some innovative techniques to help outcome 
this issue. 
Tumour Treating Fields (TTFs) 
TTFields are a non-invasive treatment for glioblastoma They are mild electric fields with low-
intensity (>0.7–3 V/cm) and intermediate frequency (100-300 kHz) that pulses through the skin 
of the scalp of patients to disrupt mitosis in cancer cells (4,31). They are used for at least 18 
hours per day, as it is proven that helps achieve a longer median overall survival (18,31). 
TTFields can be described as having an antimitotic effect as they interfere with the normal 
polymerization of microtubules in metaphase, and cell destruction by giving the septin complex 
(polar particles) a non-uniform electric field (dielectrophoresis), in the end of telophase and 
beginning of cytokinesis (24,31,32). The TTFields have an inhibitory effect only on proliferating 
cells (32) and can be used in a variety of tumour cell lines and in animal models (4). 
Following the results of the studies effectuated (phase III clinical trial Ef-11 and phase III clinical 
trial Ef-14), TTFields can be used in recurrent glioblastoma and in newly diagnosed 
glioblastoma. The results showed that the treatment with TTFields is similar to a physician’s 
choice chemotherapy being the benefit of using TTFs the superior safety and quality of life, as 
TTFields show a lower profile of toxic effects. On the other hand, the limiting element of this 
novel therapy can be the low compliance of the patient concerning the nature of the device 
(18,24,31,32). 
The randomized trial EF-14 showed also, that the addition of TTFields with the adjuvant 
chemotherapy, increases the overall survival and prolongs the progression free of cancer cells, 
constituting a “fourth cancer treatment modality” (4,24). 
Recurrent Setting 
Nitrosoureas 
Nitrosoureas are alkylating agents, which cause DNA damage and cellular death. They are 
important chemotherapeutic agents used since the 1970’s to treat glioblastoma, being the most 
used ones: lormustine, carmustine and fotemustine. However, due to a toxic profile and the 
introduction of temozolomide and other therapeutic agents for newly diagnosed glioblastoma, 
nitrosoureas are second-line treatment. (33) 
▪ Gliadel wafers 
Gliadel wafers are an alternative to TMZ and consist of biodegradable polymers containing 
carmustine, also known as BCNU (bis (bis-chloroethyl nitrosourea). The wafers are implanted 
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in the resection cavity during surgery, providing the therapeutic dose on-site (22,27). Studies 
have been made, and the results of the phase III clinical trial have revealed an improvement 
of the median survival to 21 months, when combining the gliadel wafers with concomitant TMZ 
(1,27,34,35). However, it has been demonstrated that there are toxic effects associated. There 
is the need to develop more clinical trials, and maybe design a better structure of the wafers 
to prevent toxic effects (34–36). 
▪ Lomustine (CCNU) 
Lomustine is another alkylating agent used to treat GBM. It is administered orally at a dose of 
90 to 110 mg/mq. When comparing to BCNU, lomustine is preferable considering it has a better 
toxic profile and regarding its oral formulation. (33) 
As mentioned before, the combination of lomustine and bevacizumab is being studied as 
treatment for the recurrent glioblastoma. Although results from the phase II trial seemed 
promising with an OS of 12 months, the phase III trial showed that the results achieved with 
this combination (OS of 9.7 months) are equivalent to the results when using lomustine alone 
(OS of 8.6 months). (37) 
Highlighting this, the use of CCNU or the use of CCNU and bevacizumab is being considered 
as second-line treatment, after therapy failure with TMZ (33). 
Bevacizumab 
Bevacizumab is a humanized IgG1 monoclonal antibody that targets vascular endothelial 
growth factor (VEGF) and has been approved for glioblastoma treatment, in recurrent setting, 
by the Food Drug Administration (FDA) in the USA, in 2009, being administered intra-venously 
at a dose of 10 mg/kg, every two weeks.(1,13). 
Many clinical trials were conducted to investigate the efficacy of bevacizumab. The clinical 
trials were carried in patients with newly diagnosed glioblastoma, (38–42) with recurrent 
glioblastoma (43), with bevacizumab alone (44) or in combination with other agents: irinotecan 
(45,46), lormustine (47), TMZ (48). The results obtained demonstrated that bevacizumab is 
well tolerated, that it is possible to improve survival, although this has no statistical relevance, 
as it hasn’t improved the overall survival (OS). Therefore, there are more clinical trials in 
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Innovative Therapeutic Approaches to Fight 
Glioblastoma 
 
Considering that glioblastoma is the most devastating primary tumour of the CNS, there is an 
urge to develop new therapies. Nowadays, the innovative treatments that are under 
development concern targeted therapies due to the gained knowledge on molecular 




Targeted tumour therapy uses the knowledge about what contributes to the growth, survival 
and spread of the tumour, such as, proteins, genes, molecular pathways to hit the cancer cells 
stopping their growth and survival. Targeted tumour therapies may use a variety of substances 
in order to fight the tumour such as small molecules, small molecules drug conjugates, 
monoclonal antibodies, antibody-drug conjugates (ADCs). 
▪ RTK/PI3K/MAPK Pathways 
These signalling pathways (RTK/PI3K/MAPK) play a key role in the cellular development, 
survival and differentiation. The pathways are activated by growth factors such as Epidermal 
Growth Factor (EGF), Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth  
•RTK/PI3K/MAPK Pathways
•p53 Pathway














Figure 2 – Summary of innovative therapeutics for Glioblastoma. 
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Figure 3 – The RTK/PI3K/MAPK signalling pathways. The MAPK pathway: The growth factors such as IGF, 
PDFG, TGF-α, VEGF bind to the extracellular part of the respective receptor. This results in the dimerization 
of the receptor and the autophosphorylation of a tyrosine residue in the intracellular part. The GRB2 protein 
docks to the phosphorylated tyrosine residue, through its SH2 domain and gets activated. The GRB2 then 
recognizes SOS protein that binds to its SH3 domain. Together, these proteins identify inactive Ras, which 
is connected to GDP. SOS catalyses the activation of Ras through the phosphorylation of GDP into GTP. 
Active Ras can bind to several effector proteins such as B-Raf. When B-Raf gets activated, phosphorylates 
and activates MEK, which then phosphorylates and activates ERK that leads to the kinase cascade that 
conducts to the activation of transcription factors of the AP-1 family. AP-1 controls several cellular processes 
including differentiation, proliferation, and apoptosis The PI3K pathway: This pathway starts with the 
activation of PI3K. This can be achieved either by the binding of PIP3 to Ras or with the activation of the 
receptor belonging to RTK family, by an external growth factor. This leads to dimerization and heterologous 
phosphorylation of the monomer’s constituents of the receptor. Different proteins may bind to the 
phosphorylated domain, such as IRS-1. After bonding, IRS-1-RTK becomes an active site for the PI3K, that 
can bind directly. In the second stage of this pathway, PI3K is activated and binds to PIP2. After 
phosphorylation, PIP3 is formed and can activate AKT, which is a proto-oncoprotein, with many substrates 
and effects. One of the effects is inhibition of apoptosis, made through the bonding of AKT to BAX. Another 
important effect is activation of protein synthesis. This is performed by a multi-step protein cascade. It begins 
with the activation of Rheb which activates mTOR, that, in its turn interacts with S6K. S6K binds to the large 
subunit of ribosomes and activates the translation of mRNA. 
Reprinted from Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, et al. PI3K inhibitors as new cancer 
therapeutics: implications for clinical trial design. Onco Targets Ther [Internet]. 2016 ;9:203–10. (52), used under Creative 
Commons Attribution – Non-Commercial (unported, v3.0) License. 
Abbreviations: EGF - Epidermal Growth Factor, PDGF - Platelet-Derived Growth Factor, VEGF - Vascular Endothelial Growth Factor, 
TGF-α - Transforming growth factor alpha, GRB2 - Growth factor receptor-bound protein 2, SOS – Son of Sevenless, GDP - guanosine 
diphosphate, GTP - Guanosine-5'-triphosphate, MEK (also known as, MAPKK or MAP2K) -- Mitogen-activated protein kinase kinase, 
ERK (also known as MAPK) - Mitogen-activated protein kinase, AP-1 -  Activator protein 1, PI3K - Phosphoinositide 3-kinase, RTK - 
Receptor tyrosine kinase, IRS-1 -- insulin receptor substrate 1, PIP3 - Phosphatidylinositol (3,4,5)-trisphosphate, PIP2 - 
Phosphatidylinositol 4,5-bisphosphate, AKT (also PKB) -  Protein kinase B, BAX - bcl-2-like protein 4, Rheb - Ras homolog enriched in 
brain, mTOR - mammalian target of rapamycin 
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Factor (VEGF), Transforming growth factor alpha (TGF-α), that bind to its respective growth-
factor receptor. In MAPK pathway, this causes the dimerization of the receptor and the 
autophosphorylation of a tyrosine residue in the intracellular part. This leads to a signal 
transduction cascade, that ultimately results in the activation of transcription factors, as shown 
in figure 3. In PI3K pathway, the docking of a protein into the receptor allows PI3K to be 
activated, binding to PIP2. PIP2 is phosphorylated into PIP3 and PIP3 can activate the proto-
oncoprotein ATX, also shown in figure 3. This protein has many substrates that regulates 
several cellular processes (16,49). 
These pathways can become dysregulated due to many reasons. In the MAPK pathway can 
be by activating mutations in Receptor tyrosine kinase (RTK) or Kras (gene that controls cell 
proliferation), or inactivating mutations in its negative regulator, NF1.In the PI3K pathway, it 
can be triggered by activation of the inhibitor of this signalling transduction pathway, Pten. 
These mutations can lead to a permanent activation of these pathways, leading to undesirable 
effects (16). 
The RTK/PI3K/MAPK signalling pathway is modified in 90% of the patients with glioblastoma 
which contributes to the subsistence, increase and migration of the cancer cells (16). 
Since this pathway is changed in most of GBM cases, it is one of the most appealing targets 
for GBM therapy (14). There are many molecules under evaluation.  
Sonolisib, or PX-866, is an irreversible inhibitor of the PI3K pathway and it was studied in a 
phase II trial. The results were not promising, although there were 21% of the 33 participants, 
with a durable stable disease (14,26,50). Buparlisib, a pan-PI3K inhibitor, is also under 
development. A phase II trial has revealed clinical activity when in combination with 
bevacizumab, even though, alone shows restricted effectiveness (26,51,52). 
The mammalian target of rapamycin (mTOR) is another possible target. Everolimus, 
sirolimus, temsirolimus, inhibitors of mTOR, are approved for treating other tumours, with 
significant clinical results. Now they are being studied as treatment for glioblastoma. Phase II 
clinical trials showed limited clinical efficacy, when these compounds were evaluated alone or 
in combination either with bevacizumab, TMZ and radiation or RTK inhibitor (14,26,53–56). 
An inhibitor for PI3K/mTOR is being studied in a phase I trial. It is called voxtalisib and has 
exhibited a moderate inhibition of this pathway having a safe profile, with 68% of patients 
having stable disease (14,57). 
The MAPK signalling pathway is also very interesting. About 3% of GBM patients have the 
oncogene BRAF V600E. Vemurafenib, a BRAF inhibitor has been investigated as a 
therapeutic tool and the results show potential (14,26,58–60). Another target being considered 
is sorafenib, a Raf multikinase inhibitor. Phase I/II studies have been done and have shown 
that alone or in association with TMZ, TMZ and radiation, bevacizumab or temsirolimus the 
inhibition of tumour activity has not been relevant (14,26,61–64) 
• Epidermal Growth Factor Receptor inhibitors (EGFR) 
EGFR is an essential signal of the receptor tyrosine kinase pathways and is amplified in nearly 
40% of glioblastomas and overexpressed in over 60% of GBMs (14,19). Since its upregulation 
contributes to the oncogenesis, EGFR can be an important target for GBM therapy (13,19).  
Therefore, it has been developed a first generation of EGFR inhibitors, gefitinib and erlotinib. 
They are currently being used for lung cancer with EGFR-mutated and its use has also been 
studied for GBM, but with poor results (14). A phase II clinical trial in recurrent GBM, treated 
with gefitinib, has revealed a PFS rate of 13% at 6 months and an OS of 10 months (65,66). 
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Further research with gefitinib as monotherapy or in combination has revealed a low efficacy 
when contrasted to the current treatments, due to an inconstant and inadequate inhibition of 
the EGFR pathway (13,19,67,68). Relatively to erlotinib, when alone as treatment, has poor 
activity in unselected GBM (69–71), but when in combination has a mild response (13,72,73). 
Later, a second generation of EGFR inhibitors was developed: afatinib, dacomitinib, 
neratinib. Generally, the clinical trials conducted with afatinib and dacomitinib have disclosed 
a controllable safety profile but a short efficacy when treating the glioblastoma. For neratinib, 
studies are not available, but they are currently in recruiting phase (13,14,74–77). 
Lapatinib, a dual inhibitor of EGFR and of human epidermal growth factor receptor 2 (HER2), 
is currently used as advanced or metastatic breast cancer therapy, yet, is also being 
investigated as a potential GBM treatment. Nonetheless, the phase I/II clinical trials have 
demonstrated a low activity in unselected patients when using lapatinib alone or combined with 
TMZ or pazopanib (an antiangiogenic agent) (13,14,78–81). 
Another potential therapy is the use of cetuximab, a chimeric monoclonal antibody. Phase II 
clinical trials using cetuximab were conducted and reported a safe profile but weak activity for 
recurrent GBM. When assessing its activity with bevacizumab and irinotecan, the results were 
better, even though, not superior (13,14,82–84). 
Furthermore, there is another related oncogenic, EGFR vIII that results from the deletion of 
exons 2-7 of EGFR. Almost 20% of GBMs harbour this variant oncogenic (26,85). An antibody 
drug conjugate (ADC), depatuxizumab mafodotin (previously ABT-414), is being 
investigated. It is composed of EGFR-directed monoclonal antibody, depatuxizumab, linked 
to the potent tubulin inhibitor, monomethyl auristatin F (26,86). The information provided by 
the phase I clinical studies has shown a 6 months PFS rate of 28.3% and a 6 months overall 
survival rate of 72.5%. Has also shown low toxicity, despite of the specific ocular toxicities, 
frequently, reversible blurred vision (65%) and dried eyes (29%). There is still the need of more 
studies, therefore, depatuxizumab mafodotin randomized phase II/III trials are ongoing 
(26,86,87). There is also a vaccine under development against this specific target, 
rindopepimut, that will be explained further in this thesis. 
• Platelet-Derived Growth Factor Receptor (PDGFR) 
PDGFR is another tyrosinase kinase receptor often overexpressed and altered in all types of 
glioblastoma (13,26). The activation of this pathway leads to tumour growth, and angiogenesis, 
making this receptor a target for glioblastoma therapy (13). 
Imatinib, a kinase inhibitor of PDGFR, growth factor receptor (c-KIT) and, inhibitor of BCR-
ABL, was studied in patients with glioblastoma (13,19). The results of the clinical trials 
conducted showed poor results: imatinib in monotherapy, presented a progression-free 
survival (PFS) of 16% at 6 months, in a phase II clinical trial with recurrent disease; (13,88–
91) and, imatinib in addition with hydroxyurea, showed no relevant anti-tumour activity 
(13,92,93). Despite the poor chemotherapeutic results, imatinib improved the cytotoxic effect 
of radiotherapy in GBM cell lines (19,94). 
CP-673,451, an inhibitor of PDGFR-β, is being studied in human tumour xenografts grown to 
test its efficacy against GBM. 
Multi-kinase inhibitors were also studied. Dasatinib, multi-targeted RTK inhibitor (PDGFR, c-
KIT, SRC and EPHA2), was investigated in a phase II clinical trial. The patients had recurrent 
GBM and their selection was made based on the overexpression of at least 2 dasatinib targets. 
Although it was made a meticulous selection, the results weren’t as expected, as it failed to 
improve OS (13,14,26,95). Nintedanib, inhibitor of PDGFR α/β, FGFR and VEGF, has also 
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been unsuccessful on treating patients with recurrent GBM, even with prior bevacizumab 
treatment (13,14,96,97). Sutinib, multi-targeted RTK (PDGFR, VEGF, CD117, RET, CD114 
and CD135) was also studied, in a phase II clinical trial. The results showed limited activity 
when administered alone, but further studies are necessary to search its potential activity when 
combined with alkylating agents (13,14,98). 
▪ p53 Pathway 
p53 is a tumour suppressor protein that is essential to arrest cell-cycle and inducing apoptosis 
in damaged cells (14,26). This pathway is constituted of MDM2, MDM4 (negative regulators) 
and Tp53. When there are stressful conditions, such as DNA damage, p53 is activated through 
a cascade of phosphorylation events, and depending on the type of cellular stress, there is 
upregulation or repression of genes involving cell-cycle arrest, apoptosis and DNA repair. 
Cellular levels of p53 are controlled by its negative regulators, MDM2 and MDM4, either by 
degradation of p53 or by nuclear exportation (99). 
This pathway is dysregulated in 86% of GBM cases and it is caused by direct gene (Tp53) 
mutation or deletion, or amplification of MDM2 or MDM4 (14,15,26,100). 
Based on this, there are several experiments in development to create targeted therapies of 
this mechanism. There are some studies where they tried to reactivate the p53 pathway by 
using gene therapy with an adenovirus vector or pharmacological approaches. The phase I 
trial with the adenovirus showed poor results. As for the pharmacological approaches, the 
results were equally disappointing. It is believed they had a low potency and poor BBB 
penetration (14,26,100). 
Although the previous results, there are other studies in development, targeting the MDM2. 
There is a phase I clinical trial ongoing that is expected to show promising results in the 
inhibition of this target and activation of the p53 pathway, stimulating antitumor activity, as the 
preclinical studies have shown in GBM models (14,26,100,101). 
Since most of GBM cases have an alteration in this specific pathway, exploring these as 
potential therapeutic targets can be an advantage when treating this disease (26). 
▪ Retinoblastoma protein (pRb) Pathway 
As mentioned before, the pRb pathway is disrupted in 79% of GBM cases (15).The pRb 
pathway is composed by cyclin-dependent kinases (CDKs) - CDK4, CDK6; inhibitors of the 
INK4 family, which is a family of cyclin-dependent kinase inhibitors (CKIs) of CDK4 and CDK6; 
D-type cyclins; CCND2 gene (encodes G1/S-specific cyclin-D2); CDKN2A/B gene (encodes 
p16 and p14ARF , members of INK4 family) and retinoblastoma protein 1 (Rb1). This signalling 
transduction pathway starts with D-type cyclines bonding with CDK4 or CDK6, becoming active 
complexes. Then, CDKs phosphorylate pRb which stops its activity, being regulated by 
external factors (14,102) 
All the mentioned components of this pathway are potential targets in the therapy of 
glioblastoma (14). Considering this, pre-clinical trials were enrolled to inhibit CDK4/6 
(oncogenes in a subset of GBM, essential to the growth and survival of the tumour) (103,104). 
Additionally, a Phase-2 clinical trial (NCT01227434) was conducted to evaluate the safety and 
efficacy of palbociclib (inhibitor of CDK4/6), given the previous pre-clinical data and the 
success in breast cancer therapy. The results were not pleasing, but it is believed that if 
patients are chosen considering the sequencing of Rb1 wildtype, and other pathway 
alterations, the results can give additional knowledge (105). Considering this, other clinical 
trials are under progress, exploring new results and new inhibitors of CDK4/6 such as 
ribociclib and abemaciclib, as they show promising efficacy (14,105). 
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▪ Others 
• Polyamine Biosynthetic Pathway 
Polyamine biosynthetic pathway is very important to the cells as it produces polyamines 
responsible for many cellular processes, namely, proliferation, development and growth. The 
components of this pathway are also important in the synthesis of amino acids and ribosome 
function. 
DMFO is an irreversible inhibitor of ornithine decarboxylase, which is involved in polyamine 
synthesis, being a rate-limiting enzyme (3,158). DFMO reduces tumour cell proliferation and 
inhibits a pathway of CSCs (158). There is as in vitro study that has investigated the 
association treatment between DMFO, TMZ and radiation in three GBM cell types (U87G, 
U251MG and T98G). The combination increased cell death stablishing a prospect new 
therapy. For this to happen, this combination needs more studies, especially using in vivo 
models (3). 
Immunotherapy 
Immunotherapy is known as therapy that inhibits a specific target but also stimulates the body’s 
immune system to create an innate (antigenic-nonspecific) or adaptive immune response 
(antigenic specific) against this target (14). There are many forms of immunotherapy, such as: 
targeted antibodies, cancer vaccines, adoptive cell transfer, tumour-infecting viruses, 
checkpoint inhibitors, cytokines, and adjuvants. 
▪ Adoptive cellular therapies (ACT) 
Adoptive cellular therapies are a branch in the immunotherapeutic sphere that has recently 
arisen. In this immunotherapeutic regimen, lymphocytes are taken from the patient, altered 
with the purpose of recognition of cancer cells and then infused back in the patient. 
Consequently, the lymphocytes can mark the tumour cells and neutralize them (106). 
There are different types of adoptive cell therapy that include: chimeric antigen receptor T-cell 
(CAR T-cell) therapy, tumour-infiltrating lymphocyte (TIL) therapy, T cell receptor (TCR) T cell 
therapy. 
• CAR-T Cells Therapy 
CAR T cells stands for chimeric antigen receptor T cell therapy T cells are obtained from 
peripheral blood of patients and are genetically engineered to express a CAR molecule on the 
cell membrane. This receptor is specific for antigens of the tumour (14,106,107). 
CAR T cells are currently being used in haematological malignancies, targeting the antigen 
expressed in B cells, CD19. Research is being made, regarding its use in glioblastoma. CAR 
T cells are being developed to target these GBM-specific antigens: Tyrosine Kinase-Type Cell 
Surface Receptor (HER2), Interleukin 13 receptor α 2 (IL-13Rα2) and EGFRvIII. 
In 2010, a phase I clinical trial, with a total of 17 participants, was conducted targeting HER2. 
The median OS after the infusion was 11,1 months and after diagnosis was 24,5 months. 
HER2-CAR VSTs were detected for up to 12 months after the infusion (106,108). Further 
studies are being enrolled to improve the activity of HER2-CAR VST by augmenting their 
persistence (106,109) and function (106,110,111). 
Infusion of CAR T cell in one patient with recurrent glioblastoma, targeting IL-13Rα2 revealed 
regression of the tumour with no side effects (22,112). Another trial, conducted in 3 patients 
with high grade glioma (HGG) showed similar results, with reduced expression of IL-13Rα2 
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(106,113). In an attempt to improve the outcomes, other clinical trials are being enrolled, with 
optimization of this target and the process of infusion (106,114). 
CAR T cells against EGFRvIII mutation were also design and studied in a clinical trial. 10 
patients with recurrent GBM were enrolled and attained safe and promising results. However, 
progression occurred in almost all cases and there are signs that tumours may adapt and 
escape these kinds of therapeutics (22,106,115). To supress this, a preclinical trial with 
immune-modulatory therapies is being conducted. With this adjuvant treatment, it is possible 
to stop the immunosuppression (106,116). 
CAR T cells may be a helpful tool in treating glioblastoma, although there are some issues that 
must be overcome: antigen escape and tumour heterogeneity. 
• TIL Therapy 
TIL therapy stands for tumour-infiltrating lymphocyte therapy (106). The treatment with TIL’s 
starts at the time of the resection of the tumour, where they collect these lymphocytes that are 
tumour-specific. Afterwards, they can isolate them or modify them genetically to recognize 
tumour mutations. Subsequentially, they are expanded and infused back in the patient 
(106,117,118). This therapy may have a future in treating glioblastoma, since it uses the 
patients T cells that already recognize the tumour as a treatment (106,117) .There are some 
issues that must be study carefully and overcome, such as the potential toxic effects and the 
risk of cytokine release syndrome (106,119). 
• TCR Therapy 
TCR therapy, stands for T cell receptor (TCR) T cell therapy, has revealed a successful 
outcome in metastatic melanoma. TCRs are usually expressed in T cells and they can 
specifically recognize and bind to antigens and after, induce apoptosis. The TCR therapy uses 
T cells attained from the patient’s peripheral blood. To improve the antigen recognition, they 
are genetically modified to present tumour-specific α and β chains. Afterwards, T cells are 
expanded and introduce again into the patient (106,117,120–122). 
TCR therapy has clinical application in treating metastatic melanoma, targeting the melanoma-
associated antigen recognized by T cells (MART-1) and melanoma-associated antigen A3 
(MAGE-A3), and, also in synovial sarcoma (106,123,124). Research is ongoing to access the 
use of TCR therapy also in high grade gliomas (HGG) and in GBM. (106,125) 
▪ Vaccine Therapy 
Cancer vaccines, like the regular vaccines, expose the immune system to an antigen present 
in the tumour. This first contact will stimulate the T cells, and trigger an inflammatory response 
addressing the tumour. This initial encounter will build an immune memory for upcoming 
contact (106,126). 
• Dendritic Cell Vaccines 
DCVax, a dendritic cell (DC) based cancer vaccine, uses autologous tumour lysates or tumour 
antigens to cause an immune response. Nowadays is approved in Switzerland for treatment 
of Glioblastoma (13,22,127). 
The vaccine is made upon extraction of blood from the patient, with isolation of monocytes that 
will posteriorly differentiate into dendritic cells. Afterwards, autologous tumour lysates or 
antigens are cultured with the DCs for posterior recognition of the cancer cells. Finally, the 
formed vaccine is injected into the patient (106). 
Preclinical studies using mouse models have confirmed a good response in the CNS 
(128,129). Further clinical trials have been done to verify the immune response. In 2 Phase I 
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clinical trials in patients with newly diagnosed glioblastoma and with recurrent GBM, the results 
obtained showed a good prognosis, achieving respectively, an OS of 9.6 months (with 2-year 
OS of 14,8%) and a median OS of 24 months (13,130,131). In a Phase III clinical trial, the 
results were even more encouraging. The trial was conducted in patients with newly diagnosed 
GBM and attained, for patients with methylated MGMT (n = 131 of 331), mOS of 34.7 months 
from surgery, with a 3-year survival of 46.4% (13,132,133) The DCVax has a safe profile and 
a suggested great efficacy. Although the substantial effectiveness, it is required more studies 
to evidence these results. 
In additional research, it is being investigated the combination of DCVax with standard therapy 
(22,134), with immunomodulatory therapies, as for example, pre-conditioning with potent recall 
antigen (such as tetanus/diphtheria toxoid) (22,106,135) and in combination with toll-like 
receptor agonists (22,136). In general, the results show that the combinations are safe and 
feasible. 
• Peptide Vaccines 
Peptide vaccines are made from tumour associated antigens. Since they are made from 
tumour antigens, they are not specific to one patient, having a broad range. 
As mentioned before, rindopepimut is a peptide vaccine targeting the mutated receptor, 
EGFRvIII. Early phase clinical trials have demonstrated an improvement on overall survival, 
whether using the vaccine alone or in combination with TMZ (137–139). However, new studies 
have shown no survival advantage (13,106,140,141). 
Another peptide vaccine that targets the tumour antigen HLA-restricted Wilms tumour 1 (WT1) 
is also being examined in patients with recurrent glioblastoma and with newly diagnosed GBM 
(in combination with standard treatment). The results were promising as it has shown clinical 
activity (13,14,142–144). 
SurVaxM is another peptide vaccine under development, marking survivin, an anti-apoptotic 
protein responsible for cancer cells survival, being expressed in 95% of GBM cases. A phase 
I clinical trial was conducted and the results are promising, with a safe profile an OS of 86.6 
weeks, with an increase of 56 weeks, when compared to therapy with chemotherapeutic 
agents (1,145). 
• Heat Shock Protein Vaccination 
Heat Shock proteins (HSPs) are produced when the cells are exposed to stressful 
circumstances. They stimulate the immune system, activating both innate and adaptive 
immune systems, and induce an anti-tumour immune response, by bonding to antigens and 
deliver them to antigen presenting cells (APC). Since the tumour cells have an increased 
expression of HSPs, these proteins make a useful instrument in cancer vaccine development 
to fight glioblastoma (22,106). 
The development of the vaccine follows 4 stages: resection of glioblastoma; release of HSPs, 
that primarily, connect to the tumour antigens, isolation and purification of these complexes 
(HSPs-tumour antigens) to make the vaccine and administration to the patient. Once 
administer, the HSPs-tumour antigen complexes are delivered to APCs, that presents them to 
major histocompatibility complex (MHC) class I molecules for recognition of Cytotoxic T 
lymphocytes (CTLs). CTLs then cross BBB and mark GBM cells, resulting in the anti-tumour 
response (106). 
HSP peptide complex-96 (HSPPC-96) is being studied as a patient specific vaccine 
(Prophage) against glioblastoma. The phase II clinical trial conducted, showed promising 
results due to a safe profile and significant immune response to the treatment. This study also 
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showed that pre-treatment of lymphopenia may diminish the efficacy of the vaccine. In a 
subsequent phase II clinical trial, it was investigated the use of this vaccine in combination with 
TMZ, and the results ensure the security and effectiveness when using both (22,106,146). 
More studies are currently on going, exploring new populations (paediatric population) and 
new combinations (for example, using pembrolizumab, an anti-PD-1 checkpoint inhibitor) 
(106). 
▪ Checkpoint Inhibition 
Immune checkpoints are an important tool in immune regulation to avoid autoimmunity. They 
are expressed in many cells, like T effector cells, APCs and myeloid-derived cells. Checkpoint 
inhibition, in contrast, is the treatment that targets immune checkpoints to block them, in order 
to restore the normal immune system function (106). 
Many studies are being made to verify the possibility of using checkpoint inhibitors as 
glioblastoma therapy. Although the results published so far don’t present the promising results 
expected, there is still expectations of them being used in GBM treatment. 
A phase III clinical trial using nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal 
antibody, showed no benefit in the OS. However, a small subset of patients improved their OS 
to 11 months, better that therapy with bevacizumab, which reaches an OS of 5.3 months. 
Additional analysis in this group is necessary to understand the differences in this population 
(immune status, tumour biomarkers) that led to this outcome (106,147). 
Another checkpoint inhibitor being studied is anti-Lymphocyte-activation gene 3 (LAG3) 
monoclonal antibody, named LAG525.However, the results haven’t been released yet. 
Virotherapy 
Virotherapy uses virus as therapeutic agents and comprises: oncolytic virotherapy, viral 
vectors for gene therapy and viral immunotherapy. 
Oncolytic virotherapy is based on the ability of using replicated virus, attenuated or genetically 
modified viruses to target specifically the cancer cells, inducing cell death through different 
mechanisms. Some of these virus are also immunogenic, meaning that they have the capacity 
to generate an immune response (106,148). 
Many viruses are being studied as potential glioblastoma therapy. 
A therapeutic approach with ParvOryx01, a H-1PV oncolytic virus, is being developed. A 
phase I/II 2a clinical trial was conducted on GBM and the results were promising, as 
ParvOryx01 seemed to improve survival and stimulated the immune system with an antitumor 
effect (1,149). 
PVSRIPO, the recombinant polio-rhinovirus chimera, binds to the receptor CD155 found in 
several neoplastic cells. Preclinical studies of treatment with PVSRIPO, in murine models with 
breast and prostate cancer and preclinical studies in athymic mice bearing the conventional 
subcutaneous (s.c.) or intracerebral glioma xenografts have shown promising results, as the 
tumour infection and the innate response provoked by the virus leaded to the regression of the 
tumours (106,150,151). A phase I clinical trial was conducted in 61 patients and concordantly 
with the previous results, revealed an improved overall survival with 21% of patients surviving 
between 24 and 36 months (106,152). 
Preclinical studies and phase I clinical trial were held with DNX-2401 (Delta-24-RGD) against 
high-grade glioma. This virus is an oncolytic adenovirus whose infection causes oncolytic 
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effects and anti-glioma immunity, resulting in the increasing of long-term survival 
(106,153,154). 
Zika Virus is also being studied. In vitro and in vivo studies were made, and the results were 
encouraging as zika virus has oncolytic activity against GBM stem cells. Additional research is 
needed to verify this results (106,155,156). 
It is also being investigated the possibility of using virotherapy in combination with 
chemotherapy or radiotherapy. Preclinical trials tested the use of the virus Herpes-Simplex 
increase of delivery of the virus to the tumour cells, and damage on the splitting cells. Further 
studies are needed to confirm the efficacy of these treatments (106,157,158). 
Gene Therapy 
Gene therapy, an experimental technique still under study, stands for the introduction, 
substitution or inactivation of genes in order to treat an illness. 
In the specific case of glioblastoma, there are some preclinical and clinical researches on 
going, but there aren’t many published results. These researches are exploring several 
strategies for achieving the modification in genes, such as: insertion of drug sensitivity genes, 
suicide gene therapy (using HSV thymidine kinase), transfer of wildtype p53 or p27, among 
others (22) 
A phase III clinical trial of herpes simplex virus, thymidine kinase and ganciclovir as gene 
therapy for GBM hasn’t shown promising results (22). 
In another clinical research, testing a retroviral replicating vector (RRV) - Toca 511, the results 
shown are promising. This phase I clinical trial on a patient with glioblastoma has shown 
favourable safety profile and a better OS than lomustine alone (1). 
Other Potential Therapies 
▪  Cholesterol Metabolism 
The brain has 20% of the total cholesterol of the human body. This cholesterol is synthetized 
in the brain, since the BBB is impermeable to it. The synthesis of cholesterol is of big 
importance to the development of the cancer meaning it is a possible therapy target. More 
studies are needed but there is an evidence linking the metabolism of cholesterol and the 
development of brain tumours, specifically glioblastoma (15). 
▪ Hyperthermia 
Hyperthermia is a therapy based only on the elevation of the temperature at the tumour location 
(to 41-46ºC) to damage the cancer cells. There are several types of mechanisms to induce 
hyperthermia, such as: microwaves, ultrasound, radiation, magnetic nanoparticles and thermal 
conduction. These techniques are under study, but in general the results are promising. These 
therapies have demonstrated the capacity of being used in monotherapy or in combination, 
the ability of altering the BBB, which allows for chemotherapeutic agents to reach the tumour 
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Glioblastoma is a complex tumour with a bad prognosis. There are many new treatments under 
development trying to control and/or reverse this outcome. Many of these new therapies have 
drawbacks due to many reasons: some related to the brain, an elaborate environment, that 
has many barriers such as the BBB; some related to the tumour, a heterogenous cancer, with 
many mutations in the cell pathways, and some to the therapy itself, as for example the CAR-
T cells that has a lack of long-term response. The key to resolve these issues starts with a 
better clinical trial design, molecular screening of the patients to better address the treatments.  
However, with the constant gained knowledge in the scientific field and the endless 
development of the technologies, the future for glioblastoma therapy is promising. The 
evolution of the glioblastoma standard therapies, with improvements in the surgical and 
imaging methods, with the creation of new ways to deliver the chemotherapeutic agents and 
the turning of radiation therapy into a more focalized therapy to the tumour site, are signs of 
these advances. 
Further progress is being made with innovative therapies. The vaccines, SurVax, Prophage 
and DCVax; the virotherapy, with ParvOryx01, PVSRIPO; the CAR-T Cells therapy, 
Vemurafenib, depatuxizumab mafodotin had encouraging results that conducted to a tumour 
regression and increasing of long-term survival, Sonolisib, Voxtalisib leaded to a stable 
disease in most of the patients and other molecules, such as erlotinib showed a moderate 
response, but in combination with other treatments its action was potentiated. 
Many of these innovative therapies are still being studied either alone or in combination with 
the current therapies and the novel ones. 
Since the future of Medicine lays on personalized treatments, the key to successful therapies 
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